Sale of Assets - Additional Information (Detail) - Disposal Group Not Discontinued Operations [Member] - MYDICAR [Member] - Theragene Pharmaceuticals, Inc. [Member] - USD ($) $ / shares in Units, $ in Millions		1 Months Ended		12 Months Ended
	Jan. 01, 2022	Sep. 30, 2020	May 31, 2017	Dec. 31, 2021
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Cash payment received for sale of assets under asset purchase agreement			$ 0.2
Sale of assets number of common stock shares received			475,000	475,000
Maximum cumulative cash proceeds of counter party for issuance of additional shares			$ 4.0
Maximum consideration per share of counter party for issuance of additional shares			$ 6.00
Aggregate common stock consideration value			$ 2.9
Shares repurchase by counterparty based on exercise of put options			225,000	225,000
Cost method investment with carrying value				$ 0.0
Upfront, licensee fee, milestone and other payments (excluding royalty payments) received, percentage		25.00%
Proceeds from upfront, licensee fee, milestone and other payments (excluding royalty payments) received				$ 0.3
Subsequent Event [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Proceeds from upfront, licensee fee, milestone and other payments (excluding royalty payments) received	$ 0.1
Minimum [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Shares repurchase by counterparty based on exercise of put option value			$ 1.4
Maximum [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Asset purchase agreement contingent consideration receivable			$ 45.0
Royalty receivable percentage on net sales			8.00%